Gleneagles JPMC

Tutorial 1: SWOT Analysis

Introduction

A quick introduction about the company.Established on 15th July 2002 , Gleneagles JPMC Sdn Bhd (Gleneagles) was operational on the 8th August 2002 . Gleneagles is a joint venture between Gleneagles International Pte. Ltd. a subsidiary of Parkway Group Healthcare, a major Singapore healthcare company, and the Government of Brunei Darussalam. It is the first hospital in Brunei Darussalam to set up a world-class tertiary Cardiac Centre for patients with cardiac problems.

Strengths

What does the company do well?

Cardiac Catheterisation Laboratory provides 24hrs on-site cardiac interventional services such as:

    * Cardiac catheterization (coronary angiogram)

    * Percutaneous Coronary Intervention (PCI) with newest available Drug-Eluting Stents

    * Pacemakers insertion (Permanent and Temporary)

    * Insertion of Dual chamber Implant-able Cardioverter Defibrillators (AICD)

    * BI-VEN IC

    * Atrial Septal Defect (ASD) device closure

    * Patent Ductus Arteriosus (PDA)

    * Aortic stenting

    * Electrophysio Study and Ablation

 These procedures and treatments are performed by our on-site Consultant Cardiologist together with a team of experienced and qualified Cardiac Technicians and Staff Nurses.

Weaknesses

What does the company do poorly?

High medical payment.

Lack of man power (specility area)

Opportunities

Do new markets exist for the company? Yes

Can new technologies be exploited? No

Threats

What are competitors doing well?

Conclusion

Gleneagles aims to provide services that are technologically appropriate, with emphasis on quality, innovation and health promotion. The main emphasis is to enable patients to maintain the highest possible state of health and well being. Gleneagles is committed to providing the people of Brunei as well as its neighbouring countries with the state of the art technology in Cardiology and doctors, nurses and paramedical staff of the highest caliber as well as superior standards of patient care.